Originally identified as a tumor-associated antigen in melanoma, PRAME has since been implicated in a spectrum of malignancies, including hematological and solid tumors such as non-small cell lung cancer, breast carcinoma, renal cell carcinoma, ovarian carcinoma, leukemia, synovial sarcoma, and myxoid liposarcoma [2,3,4,5,6,7,8]. This evidence concerns the gene PRAME and melanoma.